These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Association of clinical status of follicular lymphoma patients after autologous stem cell transplant and quantitative assessment of lymphoma in blood and bone marrow as measured by SYBR Green I polymerase chain reaction. Pennell N; Woods A; Reis M; Buckstein R; Spaner D; Imrie K; Hewitt K; Boudreau A; Seth A; Berinstein NL J Mol Diagn; 2006 Feb; 8(1):40-50. PubMed ID: 16436633 [TBL] [Abstract][Full Text] [Related]
29. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia. Nunes V; Cazzaniga G; Biondi A Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364 [TBL] [Abstract][Full Text] [Related]
30. Assessment of minimal residual disease in childhood non-hodgkin lymphoma by polymerase chain reaction using patient-specific primers. Sabesan V; Cairo MS; Lones MA; Perkins SL; Morris E; Sposto R; Van De Ven C; Shiramizu B J Pediatr Hematol Oncol; 2003 Feb; 25(2):109-13. PubMed ID: 12571460 [TBL] [Abstract][Full Text] [Related]
31. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321 [TBL] [Abstract][Full Text] [Related]
32. Minimal Residual Disease Assessment in Lymphoma: Methods and Applications. Herrera AF; Armand P J Clin Oncol; 2017 Dec; 35(34):3877-3887. PubMed ID: 28933999 [TBL] [Abstract][Full Text] [Related]
33. Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation. Zwicky CS; Maddocks AB; Andersen N; Gribben JG Blood; 1996 Nov; 88(9):3314-22. PubMed ID: 8896395 [TBL] [Abstract][Full Text] [Related]
34. Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms. Ferrero S; Drandi D; Mantoan B; Ghione P; Omedè P; Ladetto M Hematol Oncol; 2011 Dec; 29(4):167-76. PubMed ID: 22678691 [TBL] [Abstract][Full Text] [Related]
35. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. Corradini P; Ladetto M; Zallio F; Astolfi M; Rizzo E; Sametti S; Cuttica A; Rosato R; Farina L; Boccadoro M; Benedetti F; Pileri A; Tarella C J Clin Oncol; 2004 Apr; 22(8):1460-8. PubMed ID: 15084619 [TBL] [Abstract][Full Text] [Related]
36. Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. Donovan JW; Ladetto M; Zou G; Neuberg D; Poor C; Bowers D; Gribben JG Blood; 2000 Apr; 95(8):2651-8. PubMed ID: 10753847 [TBL] [Abstract][Full Text] [Related]
37. Sequential monitoring of minimal residual disease in acute lymphoblastic leukemia: 7-year experience in a pediatric hematology/oncology unit. Katsibardi K; Moschovi MA; Braoudaki M; Papadhimitriou SI; Papathanasiou C; Tzortzatou-Stathopoulou F Leuk Lymphoma; 2010 May; 51(5):846-52. PubMed ID: 20350276 [TBL] [Abstract][Full Text] [Related]
38. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Corradini P; Astolfi M; Cherasco C; Ladetto M; Voena C; Caracciolo D; Pileri A; Tarella C Blood; 1997 Jan; 89(2):724-31. PubMed ID: 9002976 [TBL] [Abstract][Full Text] [Related]
39. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640 [TBL] [Abstract][Full Text] [Related]